Skip to main content

05.03.2021 | Original Article

Development and external validation of a nomogram for predicting the effect of tumor size on cancer-specific survival of resected gallbladder cancer: a population-based study

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The impact of tumor size on account of the long-term survival results in gallbladder cancer (GBC) patients has been controversial. It is urgent necessary to identify the optimal cut-off value of tumor size in resected GBC, and we attempted to integrate tumor size with other prognostic factors into a prognostic nomogram to predict the cancer-specific survival (CSS) of GBC patients.

Methods

1639 patients with resected GBC were extracted from the Surveillance, Epidemiology and End Results (SEER) database. X-tile program was used to identify the optimal cut-off value of tumor size. A nomogram including tumor size was established to predict 1-, 3- and 5-year CSS based on the independent risk factors chosen by univariate and multivariable cox analyses. The precision of the nomogram for predicting survival was validated with Harrell’s concordance index (C-index), calibration curves, and receiver operating characteristic curve (ROC) internally and externally.

Results

Patients with GBC were classified into 1–13 mm, 14–63 mm and 64 mm subgroup based on the optimal cut-off for tumor size in terms of CSS. The nomogram according to the independent factors was well calibrated and displayed better discrimination power than 7th tumor–node–metastasis (TNM) stage systems.

Conclusions

The results demonstrated that increased tumor size is closely associated with the worse CSS. Our novel nomogram, which outperforms the conventional TNM staging system, showed satisfactory accuracy and clinically practicality for predicting the outcome of resected GBC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lau CSM, Zywot A, Mahendraraj K et al (2017) Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973–2013). HPB Surg 2017:1532835CrossRef Lau CSM, Zywot A, Mahendraraj K et al (2017) Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973–2013). HPB Surg 2017:1532835CrossRef
2.
Zurück zum Zitat Smith GC, Parks RW, Madhavan KK et al (2003) A 10-year experience in the management of gallbladder cancer. HPB (Oxford) 5:159–166 Smith GC, Parks RW, Madhavan KK et al (2003) A 10-year experience in the management of gallbladder cancer. HPB (Oxford) 5:159–166
3.
Zurück zum Zitat Shukla SK, Singh G, Shahi KS et al (2018) Staging, treatment, and future approaches of gallbladder carcinoma. J Gastrointest Cancer 49:9–15CrossRef Shukla SK, Singh G, Shahi KS et al (2018) Staging, treatment, and future approaches of gallbladder carcinoma. J Gastrointest Cancer 49:9–15CrossRef
6.
Zurück zum Zitat Chun YS, Pawlik TM, Vauthey JN (2018) 8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845–847CrossRef Chun YS, Pawlik TM, Vauthey JN (2018) 8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845–847CrossRef
7.
Zurück zum Zitat Zhang W, Hong HJ, Chen YL (2018) Establishment of a gallbladder cancer-specific survival model to predict prognosis in non-metastatic gallbladder cancer patients after surgical resection. Dig Dis Sci 63:2251–2258CrossRef Zhang W, Hong HJ, Chen YL (2018) Establishment of a gallbladder cancer-specific survival model to predict prognosis in non-metastatic gallbladder cancer patients after surgical resection. Dig Dis Sci 63:2251–2258CrossRef
8.
Zurück zum Zitat Yadav S, Tella SH, Kommalapati A et al (2020) A novel clinically based staging system for gallbladder cancer. J Natl Compr Cancer Netw 18:151–159 Yadav S, Tella SH, Kommalapati A et al (2020) A novel clinically based staging system for gallbladder cancer. J Natl Compr Cancer Netw 18:151–159
9.
Zurück zum Zitat Cen D, Liu H, Wan Z et al (2019) Clinicopathological features and survival for gallbladder NEN: a population-based study. Endocr Connect 8:1273–1281CrossRef Cen D, Liu H, Wan Z et al (2019) Clinicopathological features and survival for gallbladder NEN: a population-based study. Endocr Connect 8:1273–1281CrossRef
10.
Zurück zum Zitat Freedman AN, Seminara D, Gail MH et al (2005) Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97:715–723CrossRef Freedman AN, Seminara D, Gail MH et al (2005) Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97:715–723CrossRef
11.
Zurück zum Zitat Collins GS, Reitsma JB, Altman DG et al (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594CrossRef Collins GS, Reitsma JB, Altman DG et al (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594CrossRef
12.
Zurück zum Zitat Lei Z, Li J, Wu D et al (2016) Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria. JAMA Surg 151:356–363CrossRef Lei Z, Li J, Wu D et al (2016) Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria. JAMA Surg 151:356–363CrossRef
13.
Zurück zum Zitat Chen S, Liu Y, Yang J et al (2019) Development and validation of a nomogram for predicting survival in male patients with breast cancer. Front Oncol 9:361CrossRef Chen S, Liu Y, Yang J et al (2019) Development and validation of a nomogram for predicting survival in male patients with breast cancer. Front Oncol 9:361CrossRef
14.
Zurück zum Zitat Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36CrossRef Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36CrossRef
15.
Zurück zum Zitat Coutant C, Olivier C, Lambaudie E et al (2009) Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol 27:2800–2808CrossRef Coutant C, Olivier C, Lambaudie E et al (2009) Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol 27:2800–2808CrossRef
16.
Zurück zum Zitat Feng J, Polychronidis G, Heger U et al (2019) Incidence trends and survival prediction of hepatoblastoma in children: a population-based study. Cancer Commun (Lond) 39:62CrossRef Feng J, Polychronidis G, Heger U et al (2019) Incidence trends and survival prediction of hepatoblastoma in children: a population-based study. Cancer Commun (Lond) 39:62CrossRef
17.
Zurück zum Zitat Aloia TA, Jarufe N, Javle M et al (2015) Gallbladder cancer: expert consensus statement. HPB (Oxford) 17:681–690CrossRef Aloia TA, Jarufe N, Javle M et al (2015) Gallbladder cancer: expert consensus statement. HPB (Oxford) 17:681–690CrossRef
18.
Zurück zum Zitat Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591–1602CrossRef Randi G, Franceschi S, La Vecchia C (2006) Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 118:1591–1602CrossRef
19.
Zurück zum Zitat Sharma A, Sharma KL, Gupta A et al (2017) Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol 23:3978–3998CrossRef Sharma A, Sharma KL, Gupta A et al (2017) Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol 23:3978–3998CrossRef
20.
Zurück zum Zitat Zatonski WA, Lowenfels AB, Boyle P et al (1997) Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 89:1132–1138CrossRef Zatonski WA, Lowenfels AB, Boyle P et al (1997) Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 89:1132–1138CrossRef
21.
Zurück zum Zitat Wang SJ, Lemieux A, Kalpathy-Cramer J et al (2011) Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29:4627–4632CrossRef Wang SJ, Lemieux A, Kalpathy-Cramer J et al (2011) Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29:4627–4632CrossRef
Metadaten
Titel
Development and external validation of a nomogram for predicting the effect of tumor size on cancer-specific survival of resected gallbladder cancer: a population-based study
Publikationsdatum
05.03.2021
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2021
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-021-01891-2

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.